GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Cyclically Adjusted Book per Share

Novavax (Novavax) Cyclically Adjusted Book per Share : $4.72 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Novavax Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Novavax's adjusted book value per share for the three months ended in Dec. 2023 was $-5.139. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.72 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Novavax's average Cyclically Adjusted Book Growth Rate was -34.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -17.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -13.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Novavax was 8.10% per year. The lowest was -17.50% per year. And the median was -4.30% per year.

As of today (2024-05-01), Novavax's current stock price is $4.33. Novavax's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $4.72. Novavax's Cyclically Adjusted PB Ratio of today is 0.92.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 3.48.


Novavax Cyclically Adjusted Book per Share Historical Data

The historical data trend for Novavax's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Cyclically Adjusted Book per Share Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.20 8.26 8.33 7.17 4.72

Novavax Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.17 6.70 6.27 5.50 4.72

Competitive Comparison of Novavax's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Novavax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Cyclically Adjusted PB Ratio falls into.



Novavax Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novavax's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book= Book Value per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-5.139/129.4194*129.4194
=-5.139

Current CPI (Dec. 2023) = 129.4194.

Novavax Quarterly Data

Book Value per Share CPI Adj_Book
201403 18.261 99.695 23.706
201406 23.663 100.560 30.454
201409 21.945 100.428 28.280
201412 19.228 99.070 25.118
201503 29.837 99.621 38.762
201506 28.857 100.684 37.093
201509 27.205 100.392 35.071
201512 21.681 99.792 28.118
201603 13.697 100.470 17.644
201606 8.130 101.688 10.347
201609 3.671 101.861 4.664
201612 -0.409 101.863 -0.520
201703 -2.059 102.862 -2.591
201706 -4.074 103.349 -5.102
201709 -4.781 104.136 -5.942
201712 -6.295 104.011 -7.833
201803 -5.731 105.290 -7.044
201806 -4.596 106.317 -5.595
201809 -6.620 106.507 -8.044
201812 -8.736 105.998 -10.666
201903 -6.415 107.251 -7.741
201906 -7.903 108.070 -9.464
201909 -7.436 108.329 -8.884
201912 -5.750 108.420 -6.864
202003 -0.445 108.902 -0.529
202006 3.015 108.767 3.587
202009 1.691 109.815 1.993
202012 8.840 109.897 10.410
202103 14.031 111.754 16.249
202106 10.041 114.631 11.336
202109 6.117 115.734 6.840
202112 -4.637 117.630 -5.102
202203 0.836 121.301 0.892
202206 -5.334 125.017 -5.522
202209 -7.212 125.227 -7.453
202212 -7.370 125.222 -7.617
202303 -10.379 127.348 -10.548
202306 -8.001 128.729 -8.044
202309 -5.713 129.860 -5.694
202312 -5.139 129.419 -5.139

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Novavax  (NAS:NVAX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Novavax's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=4.33/4.72
=0.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Novavax was 35.13. The lowest was 0.39. And the median was 3.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Novavax Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Novavax's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Cyclically Adjusted Book per Share
Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100